Amgen eyes wider Dmab approval
Amgen wants the FDA to grant wider approval for denosumab, the company's osteoporosis drug. The company has submitted a BLA for Dmab for the reduction of fractures and other skeletal problems in advanced cancer patients. Additional filings are planned in several other markets, including Europe and Japan. Report
Comments